Treatment of granuloma annulare and related granulomatous diseases with sulfasalazine: A series of 16 cases.

OBJECTIVES: Evaluate the efficacy of sulfasalazine in treating GA, AEGCG, and IGD. METHODS: Sixteen patients were identified with granulomatous disease who were treated with sulfasalazine between September 2015 and September 2019. Outcomes were based on patients' and providers' subjective evaluations. RESULTS: Sixteen patients were included in the study (ages 56-89, four male, twelve female). Previous treatments were attempted in fifteen patients. Clinical improvement was seen in fourteen patients (87.5%). Initial improvement was noted within a mean (SD) of 66.4 (35.1) days after starting therapy, with increasing benefits over time. Ten patients (62.5%) reported complete or near complete clearance, three patients (18.8%) reported significant improvement, and one (6.3%) reported partial improvement. Twelve patients elected to stop or reduce therapy, resulting in relapse or worsening in five patients. CONCLUSIONS: Sulfasalazine may be considered as treatment for GA and GA-related conditions.